Bluebird myeloma treatment delays cancer progression: Trial


A cancer patient receives radiation treatment at a government cancer hospital in Agartala, the capital of northeastern state of Tripura on Feb 3, 2017, on the eve of World Cancer Day. CHICAGO: Patients with advanced multiple myeloma treated with bluebird bio's experimental immunotherapy lived for a median of nearly a year before their cancer worsened, according to data from a small study presented on Friday.



from Biotech News